A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Einstein, David Johnson
Choudhury, Atish Dipankar
Saylor, Philip James
Werner, Lillian
Erlander, Mark G.
Ridinger, Maya
Bubley, Glenn
机构：
[1] Beth Israel Deaconess Medcl Ctr, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Trovagene, Carlsbad, CA USA
[5] Trovagene, San Diego, CA USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS266
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David J.
    Choudhury, Atish
    Saylor, Philip
    Werner, Lillian
    Erlander, Mark
    Ridinger, Maya
    Bubley, Glenn
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [5] A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone
    Lin, Jianqing
    Sama, Ashwin Reddy
    Hoffman-Censits, Jean H.
    Kennedy, Brooke
    Kilpatrick, Deborah
    Ye, Zhong
    Yang, Hushan
    Mu, Zhaomei
    Leiby, Benjamin E.
    Lewis, Nancy
    Cristofanilli, Massimo
    Kelly, William Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.
    Lin, Jianqing
    Sama, Ashwin Reddy
    Hoffman-Censits, Jean H.
    Kilpatrick, Deborah
    Yang, Hushan
    Mu, Zhaomei
    Lelby, Benjamin E.
    Lewis, Nancy
    Cristofanilli, Massimo
    Kelly, William Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    [J]. UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [8] A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
    Lin, Jianqing
    Patel, Sheel A.
    Sama, Ashwin R.
    Hoffman-Censits, Jean H.
    Kennedy, Brooke
    Kilpatrick, Deborah
    Ye, Zhong
    Yang, Hushan
    Mu, Zhaomei
    Leiby, Benjamin
    Lewis, Nancy
    Cristofanilli, Massimo
    Kelly, William Kevin
    [J]. ONCOLOGIST, 2016, 21 (11): : 1296 - 1297
  • [9] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
    Nuria Romero-Laorden
    Rebeca Lozano
    Anuradha Jayaram
    Fernando López-Campos
    Maria I. Saez
    Alvaro Montesa
    Ana Gutierrez-Pecharoman
    Rosa Villatoro
    Bernardo Herrera
    Raquel Correa
    Adriana Rosero
    María I. Pacheco
    Teresa Garcés
    Ylenia Cendón
    Ma Paz Nombela
    Floortje Van de Poll
    Gala Grau
    Leticia Rivera
    Pedro P. López
    Juan-Jesús Cruz
    David Lorente
    Gerhardt Attard
    Elena Castro
    David Olmos
    [J]. British Journal of Cancer, 2018, 119 : 1052 - 1059
12345